Regentis postpones shareholder meeting for lack of quorum
Regentis Biomaterials Ltd. convened its Annual General Meeting of Shareholders on July 2, 2026, but the meeting was adjourned for one week due to lack of quorum.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
6-K
Rhea-AI Filing Summary
Regentis Biomaterials Ltd. convened its Annual General Meeting of Shareholders on July 2, 2026, but the meeting was adjourned for one week due to lack of quorum. The meeting will be reconvened on July 9, 2026 at 3:00 p.m., Israel time, at the offices of the Company’s attorneys in Tel Aviv.
Key Figures
Initial meeting date: July 2, 2026
Reconvened meeting date: July 9, 2026
Reconvened meeting time: 3:00 p.m., Israel time
3 metrics
Initial meeting date
July 2, 2026
Date the Annual General Meeting of Shareholders was first convened
Reconvened meeting date
July 9, 2026
Date the adjourned Annual General Meeting will be reconvened
Reconvened meeting time
3:00 p.m., Israel time
Time of the reconvened Annual General Meeting on July 9, 2026
Key Terms
Form 6-K, foreign private issuer, Annual General Meeting of Shareholders, quorum, +1 more
5 terms
Form 6-K regulatory
"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
foreign private issuer regulatory
"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
quorum financial
"the Annual General Meeting was adjourned for one week ... due to lack of quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
Form 20-F regulatory
"whether the registrant files or will file annual reports under cover Form 20-F"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Regentis Biomaterials Ltd. (RGNT) announce in this Form 6-K?
Regentis Biomaterials Ltd. reported that its Annual General Meeting of Shareholders, convened on July 2, 2026, was adjourned for one week due to lack of quorum. The company also provided the new date, time, and location for the reconvened meeting.
Why was Regentis Biomaterials Ltd.’s 2026 Annual General Meeting adjourned?
The Annual General Meeting of Shareholders held on July 2, 2026 was adjourned because there was a lack of quorum. Without sufficient shareholder presence or representation, the meeting could not proceed with its agenda and therefore had to be postponed by one week.
When will Regentis Biomaterials Ltd. (RGNT) reconvene its postponed Annual General Meeting?
The postponed Annual General Meeting will be reconvened on Tuesday, July 9, 2026 at 3:00 p.m., Israel time. This reconvened session continues the original meeting that began on July 2, 2026 but was adjourned after quorum was not reached.
Where will Regentis Biomaterials Ltd.’s reconvened Annual General Meeting take place?
The reconvened Annual General Meeting will be held at the offices of the company’s attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel, as stated in the notice.
What type of SEC reports does Regentis Biomaterials Ltd. (RGNT) file as a foreign issuer?
Regentis Biomaterials Ltd. is a foreign private issuer that files its annual reports under cover of Form 20-F. This Form 6-K is a current report used to update U.S. investors on specific events between those annual Form 20-F filings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
